Gene therapy trial targets rare brain disease

NCT ID NCT04680065

First seen Jan 31, 2026 · Last updated Apr 25, 2026 · Updated 10 times

Summary

This early-stage study tests whether a gene therapy called AAV2-GDNF is safe for people with Multiple System Atrophy (MSA), a rare and serious brain disorder. Nine adults aged 35-75 with MSA will receive either the gene therapy or a placebo. The main goal is to check for side effects, while also seeing if the treatment might help with symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • NYU Langone Health

    New York, New York, 10016, United States

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

  • Quest Research Institute

    Farmington Hills, Michigan, 48334, United States

  • The Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

  • University of California Irvine

    Irvine, California, 92697, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.